



Implementation of a liquidity agreement with Natixis

Bagneux, France, April 26, 2012 - DBV Technologies (Euronext: DBV – ISIN: FR0010417345), creator of Viaskin®, a new standard in the treatment of allergy, announced today that, as of April 27, 2012, the company entrusts NATIXIS with the implementation of a liquidity agreement on DBV Technologies shares traded on NYSE Euronext Paris, in accordance with the Charter of Ethics established by the AMAFI of March 8, 2011 and approved by the decision of the Autorité des Marchés Financiers of 21 March 2011. €300 000 (three hundred thousand euros) have been allocated for the implementation of this liquidity contract.

About DBV Technologies:

DBV Technologies is opening up a decisive new approach to the treatment of allergy – a major public health issue that is constantly increasing in prevalence. Food allergies represent a true handicap in everyday life for millions of people and thus constitute a major unmet medical need. DBV Technologies (incorporated in 2002) has developed a unique, proprietary, worldwide-patented technology for administering an allergen to intact skin and avoiding massive transfer to the blood. The Viaskin® technology combines efficacy and safety as part of a treatment that seeks to improve the patient's tolerability of peanut and thus considerably lower the risk of a systemic, allergic reaction in the event of accidental exposure to the allergen. The company's significant development program has taken this revolutionary method through to the industrial stage. The product's clinically proven safety of use enables the application of effective desensitization techniques (the efficacy of which is acknowledged worldwide) in the most severe forms of the allergy.

DBV Technologies is focusing on food allergies (milk and peanut) for which there are currently no effective treatments. It has designed two products: Viaskin® Peanut and Viaskin® Milk. The development clinical program for Viaskin® Peanut has received Fast Track designation from the US Food and Drug Administration. The company will subsequently develop a Viaskin® patch for young children with house dust mite allergy – a true public health issue because this pathology is one of the main risk factors for childhood asthma.

DBV Technologies shares are traded on segment C of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345).

For more information on DBV Technologies, please visit our website: www.dbv-technologies.com

Contacts

David Schilansky

Chief Financial Officer

DBV Technologies

Tél. : +33(0)1 55 42 78 75

david.schilansky@dbv-technologies.com

NewCap.

Financial Communication and investors relations

Emmanuel Huynh / Alexandra Schiltz

Tél. : +33(0)1 44 71 94 94

dbv@newcap.fr